Would be great to get a solid timeline with key catalysts from management. Hard to follow at the moment when there isn't any timelines to be held to.
12+ months trial has been mentioned in the past. Currently we are near 6 months in with 30 healthy patients scanned. Stage 2 is up to 150 acute stroke/stroke mimic participants. Stage 3 to be advised, and then onto the validation phase (sensitivity/specificity), endpoint and sample size to be advised. I imagine they could be waiting on feedback/guidance from the FDA for this.
Hopefully we can expect the administrative 'green light' from the two other hospitals soon. Excited to see the how the data stacks up once acute stroke patients begin to be scanned...
Would be great to get a solid timeline with key catalysts from...
Add EMV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.91 |
Change
0.025(1.33%) |
Mkt cap ! $163.1M | |||
| Open | High | Low | Value | Volume |
| $2.00 | $2.00 | $1.91 | $28.37K | 14.24K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 967 | $1.91 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $2.06 | 1815 | 1 |
View Market Depth
| Last trade - 16.10pm 14/06/2024 (20 minute delay) ? |
|
|||||
|
Last
$1.92 |
Change
0.025 ( 0.26 %) |
||||
| Open | High | Low | Volume | ||
| $1.99 | $2.00 | $1.92 | 1292 | ||
| Last updated 15.56pm 14/06/2024 ? | |||||
| EMV (ASX) Chart |